Anna Asklid

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: ACTA ONCOLOGICA. 2023;62(10):1348-1356
Complications after proton radiotherapy in children, focusing on severe late complications. A complete Swedish cohort 2008-2019
Martinsson U; Svard A-M; Witt Nystrom P; Embring A; Asklid A; Agrup M; Haugen H; Frojd C; Engellau J; Nilsson MP; Isacsson U; Kristensen I; Blomstrand M
Article: CLINICAL ONCOLOGY. 2023;35(9):571-575
Re-irradiation in Paediatric Tumours of the Central Nervous System: National Guidelines from the Swedish Workgroup of Paediatric Radiotherapy
Embring A; Blomstrand M; Asklid A; Nilsson MP; Agrup M; Svard A-M; Frojd C; Martinsson U; Kristensen IF; Engellau J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(3):426-432
Risk-adapted bendamustine plus rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients
Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Osterborg A; Hansson L
Article: LEUKEMIA AND LYMPHOMA. 2020;61(9):2136-2144
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy
Asklid A; Sylvan SE; Mattsson A; Winqvist M; Johansson H; Osterborg A; Hansson L
Article: HAEMATOLOGICA. 2019;104(4):797-804
FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgard S; Kimby E; Norin S; Andersson P-O; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Osterborg A; Hansson L
Article: ANNALS OF HEMATOLOGY. 2017;96(10):1681-1691
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
Hansson L; Asklid A; Diels J; Eketorp-Sylvan S; Repits J; Soltoft F; Jaeger U; Osterborg A
Article: HAEMATOLOGICA. 2016;101(12):1573-1580
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Osterborg A

Alla övriga publikationer

Thesis / dissertation: 2020
Real-world studies on B-cell malignancies
Asklid, Anna
Letter: HAEMATOLOGICA. 2019;104(5):E208-E210
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Winqvist M; Andersson P-O; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Spath F; Hansson L; Osterborg A
Letter: LEUKEMIA AND LYMPHOMA. 2017;58(5):1219-1223
Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013
Asklid A; Winqvist M; Sylvan SE; Mattsson A; Bjorgvinsson E; Soltoft F; Repits J; Diels J; Osterborg A; Hansson L
Meeting abstract: BLOOD. 2015;126(23):1745
Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
Hansson L; Winqvist M; Asklid A; Andersson P-O; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Osterborg A

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2020

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI